Takeda Pharmaceutical Company Limited

Shionogi Company Limited

Nippon Telegraph and Telephone Corporation

Kabushiki Kaisha Powrex

Nec Platforms, Ltd.

Daikin Industries, Ltd.

Makoto Kobayashi

Shuji Hinuma

Ryo Fujii

Haruo Koike

Yugo Habata

Yasuaki Ito

Toshio Tanaka

Hideyuki Tanaka

Yoshiyuki Shibuya

Masaki Hosoya

Kunihiko Inui

Masahiko Nagai

Masataka Harada

Kazunori Nishi

Jinichi Yonemori

Shoji Fukusumi

Kazuhiro Ogi

Satoshi Hara

Shoichi Ohkubo

Takuya Nagato

Koji Hasegawa

Hiromi Sasaki

Seigo Yamamoto

Hitoshi Niinuma

Yuji Kawamata

Yukio Toyoda

Tadatoshi Hashimoto

Li Bao

Hiromi Yoshida

Kohji Fukatsu

Hideki Kizawa

Yasuhiro Tanaka

Shoichi Okubo

Susumu Natsuyama

Nobuyuki Watanabe

Kazuyoshi Otaki

Kenji Nagatsuma

Yoshiyuki Kanoh

Ran Tabata

Koji Hisazumi

Toru Morimoto

Shigeru Igaki

A continuous particle manufacturing apparatus comprises a particle drawing section configured to draw particles out of a processing container, a sorting section configured to sort the particles drawn by the particle drawing section into processed particles and unprocessed particles, a discharge section to which the processed particles sorted out by the sorting section are discharged, and a particle returning section configured to return, into the processing container, the unprocessed particles sorted out by the sorting section, the particle returning section being configured to blow the unprocessed particles toward an inner wall surface of the processing container together with an air stream.

Continuous particle manufacturing device

In a telephone switching apparatus equipped with an automatic call recording function, when recording of a call is started, a PB signal cannot be sent by operating a button any longer. Further, a user mistakenly assumes that there is a problem because the PB signal cannot be sent. Means capable of selecting, when recording means starts recording of a call, whether a PB signal is sent or not is provided, thus making it possible to send a PB signal.

Telephone switching apparatus and method, and program

An agent for regulating 14273 receptor function, which is useful as a preventing or treating drug for diabetes mellitus, hyperlipidemia or the like, is provided. An agent for regulating 14273 receptor function comprising a compound containing an aromatic ring and a group capable of releasing a cation.

Receptor function regulating agent

By using a G protein-coupled receptor protein comprising an amino acid sequence, which is the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, and an ionizable metal element or a salt thereof, an agonist for or an antagonist to the above receptor protein or a salt thereof can be efficiently screened.

Screening method for binding property or signal transduction alterations

By using FPRL1 ligand, which comprises the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 17 or SEQ ID NO: 21, and FPRL1, an efficient screening for FPRL1 agonist or FPRL1 antagonist can be performed.

FPRL1 ligands and use thereof

The use of a G-protein coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof and a ligand peptide comprising the amino acid sequence represented by any of SEQ ID NO: 3 to 7, or a salt thereof, enables efficient screening of an agonist or antagonist for the above receptor protein or a salt thereof.

Methods of screening for ligands for FPRL2

This invention relates to a DNA containing uncoupling protein-2 (UCP-2) promoter region containing the regulator sequence, a transformant transformed with the DNA, a method for screening a compound or its salt that promotes or inhibits UCP-2 promoter activity characterized by use of the transformant, a method for screening an antiobestic drug, an antidiabetic drug, a depressor, an antihyperlipemic drug, and an antipyretic drug characterized by use of the transformant, a kit for screening a compound or its salt that promotes or inhibits UCP-2 promoter activity characterized by use of the transformant, and pharmaceutical composition containing a compound or its salt that promotes or inhibits UCP-2 promoter activity obtained using the screening method or the screening kit.

Ucp-2 promoter and use thereof

A fluidized bed apparatus has a rotary rotorarranged at the bottom center thereof, a disintegrator mechanismarranged above the rotary rotor, and a cylindrical draft tubeinstalled above the disintegrator mechanism. A fluidizing gas jetted from a gas dispersion platecauses powder particles P in a processing containerto form a fluidized bed in which they circulate so as to ascend through the gap between the outer periphery of the rotary rotorand the bottom inner wall of the processing container, the space between the disintegrator mechanismand the inner wall of the processing container, and the space between the outer periphery of the draft tubeand the inner wall of the processing container, and descend through the inner portion of the draft tube

Fluidized bed device

By using (1) a G protein-coupled receptor protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or its salt and (2) a fatty acid or an eicosanoid, a compound or its salt that can change the binding properties of the receptor protein or its salt to the fatty acid or the eicosanoid can be screened efficiently.

Screening method

A method for producing a compound represented by the general formula (I-A) or the general formula (I-B), comprising the following step: wherein Ris an optionally substituted lower alkyl, and the like; Ris a lower alkyl or an optionally substituted aralkyl, and the like; Ris a lower alkyl, characterized in that a compound represented by the general formula (II-A) or the general formula (II-B) is treated with thionyl chloride.

Processes for the preparation of oxo-oxazoline or alloamino acid derivatives

A method for producing a compound represented by the general formula (I-A) or the general formula (I-B), comprising the following step:wherein Ris an optionally substituted lower alkyl, and the like; Ris a lower alkyl or an optionally substituted aralkyl, and the like; Ris a lower alkyl, characterized in that a compound represented by the general formula (II-A) or the general formula (II-B) is treated with thionyl chloride.

Growing community of inventors

Hyogo, Japan

Makoto Kobayashi